Tesamorelin vs Sermorelin vs CJC-1295: GHRH Research Peptide Comparison
Three peptides dominate the GHRH (growth hormone-releasing hormone) research space — Tesamorelin, Sermorelin, and CJC-1295. They are all GHRH-receptor agonists, but they differ on one critical axis: how long they stay active. That single property — half-life — reshapes everything from the pulsatility of downstream GH release to which research protocol they fit.
The single-line answer
Sermorelin is the native GHRH 1-29 fragment — short, pulsatile, the closest analogue to physiological GHRH. Tesamorelin is a stabilised 44-amino-acid full GHRH analogue with the strongest clinical trial program of the three. CJC-1295 with DAC is a long-acting modification engineered for ~6-8 day half-life via albumin binding.
| Compound | Structure | Half-life | Clinical Stage |
|---|---|---|---|
| Sermorelin | GHRH 1-29 fragment (29 aa) | ~10-20 min | FDA-approved (Geref, discontinued) |
| Tesamorelin | Modified 44-aa GHRH (trans-3-hexenoyl) | ~26 min | FDA-approved (Egrifta, 2010) |
| CJC-1295 (DAC) | GHRH 1-29 + DAC (albumin-binding) | ~6-8 days | Phase 1/2 only — not approved |
Why half-life matters more than potency
Native GHRH has a plasma half-life of about 7 minutes. That short window is biologically purposeful: the pituitary releases growth hormone in pulses, primarily during slow-wave sleep, and the brief lifetime of endogenous GHRH is what keeps that pulsatility intact. Any GHRH analogue has to make a trade-off between preserving that pulsatile pattern and being practical to dose.
Each of the three peptides made a different call:
- Sermorelin keeps the trade-off closest to native GHRH — very short half-life, fully pulsatile, but requires daily (or twice-daily) administration in research protocols.
- Tesamorelin takes the middle road — its modified structure extends half-life to ~26 minutes while preserving the pulsatile GH response. Once-daily dosing.
- CJC-1295 DAC goes to the opposite extreme — multi-day exposure via albumin binding. Convenient dosing, but it produces a near-continuous GH-axis activation (sometimes called "GH bleed") rather than discrete pulses.
Worth noting: there are two CJC-1295 variants in circulation — CJC-1295 DAC (with the albumin-binding Drug Affinity Complex, ~6-8 day half-life) and CJC-1295 No-DAC (also called Modified GRF 1-29, half-life ~30 minutes). They behave more like Sermorelin/Tesamorelin than like the long-acting DAC version. Always check which variant a paper or product refers to.
Clinical trial data
This is where the three diverge sharply. Trial data only exists for the two with completed clinical programs:
| Compound | Phase 3 Trials | Key Endpoint Achieved | Regulatory Status |
|---|---|---|---|
| Sermorelin | FDA approval 1990s (paediatric GH deficiency) | Stimulated GH release, increased growth velocity | Approved as Geref — discontinued commercially |
| Tesamorelin | Falutz 2010, Stanley 2014 — both NEJM/JAMA-level Phase 3 | −15.2% VAT (visceral adipose tissue) at 26 weeks | Approved as Egrifta (2010) for HIV lipodystrophy |
| CJC-1295 | Phase 1 PK study (Teichman 2006); no Phase 3 | Sustained IGF-1 elevation at single dose | Not approved — Phase 2 program halted |
Tesamorelin's clinical record is the most relevant for research models: two large Phase 3 RCTs showing reproducible reductions in visceral adipose tissue, normalised triglycerides, and reduced liver fat — all in humans, all peer-reviewed at NEJM/JAMA level. This is why Tesamorelin is the GHRH analogue most often cited as a reference compound in current metabolic and body-composition research.
How the three differ in research use
Sermorelin — closest to physiological pattern
For research protocols where you want to mimic native GHRH-like pulsatility — circadian GH-axis studies, sleep-pulse research, paediatric GH-deficiency models — Sermorelin is the most appropriate choice. It is also the most "fragile" GHRH analogue, requiring careful handling and frequent dosing.
Tesamorelin — strongest body-composition research record
For research on visceral adipose tissue, hepatic fat (NAFLD/NASH models), and the metabolic effects of pulsatile GH stimulation, Tesamorelin is the reference compound. Its 44-amino-acid structure is also closer to native GHRH than the 29-amino-acid Sermorelin/CJC backbones, which matters for full-length GHRH receptor binding studies.
CJC-1295 DAC — convenience over physiology
CJC-1295 DAC has the most practical dosing schedule (once-weekly research dose), and it produces the most sustained IGF-1 elevation. The trade-off is that the constant GHRH-receptor stimulation departs from natural physiology — for research questions where pulsatility itself is the variable being studied, this is a problem rather than a feature.
The Ipamorelin / GHRP angle
In a meaningful percentage of research protocols, GHRH analogues are combined with GHS-R1a agonists (ghrelin mimetics like Ipamorelin, GHRP-2, GHRP-6, Hexarelin). The two receptors are independent and the GH-release effects are synergistic — combined administration produces a larger GH peak than either alone. The most commonly studied pairings are:
- Sermorelin + Ipamorelin — short pulsatile pairing, popular in age-related GH research
- CJC-1295 + Ipamorelin — long-acting pairing with the most public research data, often described as the "GH pulse stack"
- Tesamorelin + Ipamorelin — less commonly studied but mechanistically clean given Tesamorelin's pulsatile pattern
Need research-grade Tesamorelin in the UAE?
HPLC ≥ 98.5% purity · Lot-specific COA · 24h cold-chain delivery · 5 mg and 10 mg flagship vials
View Tesamorelin product pagePractical research notes — handling and reconstitution
Stability
All three are lyophilized powders supplied frozen or refrigerated. Tesamorelin is the most stability-sensitive of the three (the modified N-terminus is more prone to degradation than the simpler GHRH 1-29 backbone). Sermorelin and CJC-1295 are relatively forgiving. Once reconstituted, all three require refrigeration at 2-8°C and should be used within ~28 days.
Reconstitution volume
For a 10 mg Tesamorelin vial, 3-5 mL of bacteriostatic water is the standard reconstitution volume. For Sermorelin and CJC-1295, 2-3 mL is typical for 5 mg vials. Always swirl — do not vortex or shake (peptide chains can shear).
Storage post-reconstitution
2-8°C, protected from light, used within 28 days. The benzyl alcohol in bacteriostatic water preserves the solution for multi-dose research over that window. Plain sterile water has no preservative and must be used single-dose.
Where each fits in a 2026 research portfolio
- If your research question is about pulsatile physiology: Sermorelin. Its short half-life is the feature, not a bug.
- If your research question is about body composition / VAT / hepatic fat: Tesamorelin. The clinical record is decisive.
- If your research question is about sustained GHRH-receptor activation: CJC-1295 DAC. The unique long-acting profile fills a niche the other two cannot.
Companion peptides commonly stacked with GHRH analogues
Beyond the Ipamorelin pairing already mentioned, two peptides are frequently co-administered in our customer research protocols:
- Retatrutide — incretin triple agonist; combined body-composition research (incretin-driven weight loss + GH-axis stimulation).
- GHK-Cu — copper tripeptide for dermal-collagen research alongside the IGF-1 effects of the GH axis.
Frequently asked questions
Is Tesamorelin the same as Sermorelin?
No. Both are GHRH analogues but with different structures and pharmacology. Sermorelin is the native GHRH 1-29 fragment (29 amino acids). Tesamorelin is a stabilised 44-amino-acid analogue with an N-terminal modification that extends half-life ~3-fold compared to native GHRH.
Why was CJC-1295 never approved?
Phase 1 PK data were promising, but Phase 2 development was halted following safety signals during early human trials in the mid-2000s. It remains a research-only compound. CJC-1295 reference material is supplied for laboratory and research use, not for human or veterinary administration.
Which GHRH peptide is best for fat loss research?
On the published evidence, Tesamorelin — two Phase 3 RCTs documented reductions in visceral adipose tissue, hepatic fat, and triglycerides at 26-week endpoints. The Falutz 2010 and Stanley 2014 trials are the foundation papers; both are open-access at JCEM and JAMA respectively.
Can these peptides be used for human treatment?
Tesamorelin is FDA-approved as Egrifta for the specific indication of HIV-associated lipodystrophy under prescription. It is not approved for general use. Sermorelin's commercial approval has been discontinued. CJC-1295 has never been approved. Reference material supplied by REVIVE LAB UAE is sold strictly for laboratory research use, not for human or veterinary administration.
References
- Falutz J et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients With Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304.
- Stanley TL et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014;312(4):380-389.
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53.